Kamada (KMDA) announced the filing of a Biologics License Application (BLA) in the U.S. seeking approval of Kamada's post-exposure rabies treatment human anti-rabies immune globulin (IgG). A decision is expected in mid-2017. If all goes well, the commercial launch by Kedrion will commence soon thereafter.